18 November 2011
Co-Authors
Justin Schack
Managing Director
Joe Gawronski
President and COO
Rosenblatt Securities Inc.
New York +1 212 607 3100
Dublin +353 1 855 9125
Inquiries to
globalexchangeanalysis@rblt.com
TRADING TALK
NYX, DB1 Offer Remedies to EU: Quick Thoughts
The News
DB1 and NYX today announced that they submitted yesterday a remedy proposal, in connection with their proposed merger, to the European Commission’s Directorate General for Competition. As part of its review of the deal the DG, as expected, on October 5 issued a formal “statement of objections” outlining its concerns about the deal’s impact on competition. The companies’ remedy proposal is designed to address those concerns, which reportedly are focused on derivatives trading and clearing.
|
|